Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma
AstraZeneca has completed its $350m sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma.
Manufacturing
-
07 Dec 2018
-
22 Nov 2018
Cambrex to acquire contract drug developer Avista Pharma for $252m
Life sciences company Cambrex has agreed to acquire Avista Pharma Solutions, a North Carolina-based contract development, manufacturing, and testing organization, for about $252m.
-
07 Nov 2018
AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m
AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.
-
06 Nov 2018
Quotient Sciences extends formulation and manufacturing operations in UK
Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading facility, UK.
-
31 Oct 2018
Grünenthal to buy AstraZeneca’s European rights to two drugs for $922m
German pharma company Grünenthal has agreed to acquire certain rights to AstraZeneca’s Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) for a sum of up to $922m.
-
30 Oct 2018
EQT offers to buy Karo Pharma for $654m
Private equity firm EQT has proposed to acquire 100% of Karo Pharma, a Swedish pharma company, for around SEK5.97bn ($654m).
-
17 Oct 2018
Quotient Sciences opens early-phase formulation and manufacturing plant in US
Drug development services provider Quotient Sciences has opened a 45,000ft² manufacturing facility near Philadelphia, in Garnet Valley, Pennsylvania.
-
15 Oct 2018
Dr. Reddy’s to sell API manufacturing business unit in Hyderabad, India
Dr. Reddy’s Laboratories has agreed to divest its its API manufacturing business unit located in Jeedimetla, Hyderabad, located in the Indian state of Telangana, to generics pharmaceutical firm Therapiva Private.
-
09 Oct 2018
eTheRNA immunotherapies opens mRNA manufacturing facility in Belgium
Clinical-stage firm eTheRNA immunotherapies has opened a mRNA facility in Belgium for production of mRNA immunotherapies.
-
01 Oct 2018
Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee
Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.